Saxagliptin
Back to searchMolecule Structure
Scientific Name
Saxagliptin
Description of the Drug
Saxagliptin is an DPP-4 inhibitor used for the management of type 2 diabetes mellitus.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06335
http://www.drugbank.ca/drugs/DB06335
Brand Name(s)
Not Available
Company Owner(s)
Astrazeneca Ab
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Dipeptidyl peptidase IV | SINGLE PROTEIN | INHIBITOR | CHEMBL284 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL17168 | |||
| PharmGKB | PA165958362 | |||
| Human Metabolome Database | HMDB0015634 | |||
| DrugBank | DB06335 | |||
| PubChem: Thomson Pharma | 16328544 | 16675586 | ||
| PubChem | 11243969 | |||
| LINCS | LSM-45955 | |||
| BindingDB | 50225074 | 11542 | ||
| EPA CompTox Dashboard | DTXSID7048580 | |||
| DrugCentral | 4114 | |||
| Brenda | 138960 | 2058 | 39011 | 39903 |
| Guide to Pharmacology | 6316 | |||
| rxnorm | SAXAGLIPTIN | SAXAGLIPTIN HYDROCHLORIDE | SAXAGLIPTIN ANHYDROUS | ONGLYZA |
| PubChem: Drugs of the Future | 57304394 | |||
| ChEBI | 71272 |
